By Christopher Snowbeck From Star Tribune MINNEAPOLIS—A subset of COVID-19 patients who received infusions of laboratory-made antibodies ran a lower risk of requiring hospital care for their illnesses, according to a Mayo Clinic study released Monday. The report in the journal Lancet EClinical Medicine suggests that certain monoclonal antibody treatments can help patients with mild to moderate symptoms who are at high risk of serious COVID-19 illness due to other health conditions. Mayo Clinic was the first health system in Minnesota last year to offer certain COVID-19 patients the antibody infusions, which must be given shortly after patients get sick. Former President Donald Trump received an early version of the treatment when he took ill with the pandemic virus last year. “These are excellent results with reductions in hospitalizations,” Dr. Raymund Razonable, a Mayo Clinic infectious diseases specialist and senior author of the study, said in an interview. “Among [high-risk] …